D

M

DAL BELLO , Mg

Last name: DAL BELLO

First name: Mg

2008 (v1)

Publication

Metadata-only

Difference in skin toxicity incidence between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC)

GROSSI, FRANCESCO CATANIA, GIANLUCA Defferrari, C

No description

Uploaded on: April 14, 2023
2007 (v1)

Publication

Metadata-only

Disease stabilization as a surrogate end point in advanced non small cell lung cancer patients treated with erlotinib or gefitinib

GROSSI, FRANCESCO CATANIA, GIANLUCA Brianti, A

No description

Uploaded on: April 14, 2023
2015 (v1)

Publication

Metadata-only

Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.

Coco, S TRUINI, ANNA Alama, A

The epidermal growth factor receptor (EGFR) signalling is one of the most deregulated pathways in non-small cell lung cancer (NSCLC). Recently, the development of novel irreversible tyrosine kinase inhibitors (TKI), such as afatinib, has significantly improved the survival of advanced NSCLC patients harbouring activated EGFR mutations. However,...

Uploaded on: December 5, 2022